BTG2 is a tumor suppressor that plays a role in the p53-dependent component of the DNA damage response and its low expression correlates with more severe disease in breast and prostate cancer [26], so it is likely that BTG2 plays an important role in contributing efficacy of these drugs for treatment of colorectal cancer. The gene discussed is TP53; the disease is prostate carcinoma.